Comparing the Efficacy of Ravulizumab Versus Efgartigimod Among AChR-AB Positive Generalized Myasthenia Gravis (P9-9.009)

Muhammad Ismail; Fen Bao; Mahmoud Elkhooly

doi:10.1212/wnl.0000000000217583

June 9, 2026Neurology

Comparing the Efficacy of Ravulizumab Versus Efgartigimod Among AChR-AB Positive Generalized Myasthenia Gravis (P9-9.009)

View Full Paper

Ask AI

Bookmark

Share

Key Points

This study aims to compare the effects of ravulizumab and efgartigimod on myasthenia gravis symptoms.
Examined effects of ravulizumab and efgartigimod on functional scales
Evaluated Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG)
Focused on patients with AChR-AB positive generalized myasthenia gravis.
Both treatments were evaluated on Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scales.

Implication

Compares ravulizumab and efgartigimod efficacy in AChR-AB positive myasthenia gravis, indicating therapeutic insights.

Abstract

This study examined the effect of ravulizumab and efgartigimod on various functional scales, including Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ismail et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf300faef96ed7f0558ec https://doi.org/10.1212/wnl.0000000000217583

View Full Paper

Ask AI

Bookmark

Share

Comparing the Efficacy of Ravulizumab Versus Efgartigimod Among AChR-AB Positive Generalized Myasthenia Gravis (P9-9.009)

Key Points

Implication

Abstract

Discussion

Cite This Study

Comparing the Efficacy of Ravulizumab Versus Efgartigimod Among AChR-AB Positive Generalized Myasthenia Gravis (P9-9.009)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading